Fangzhou and Innovent Biologics Partner on AI-Powered Weight Management Solutions

Posted on by

SHANGHAI, Sept. 10, 2025 – Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a prominent provider of AI-powered Internet healthcare solutions, has entered into a strategic partnership with Innovent Biologics. This collaboration aims to merge digital health services with advanced therapies for metabolic diseases and weight management. The signing ceremony was attended by Dr. Xie Fangmin, Fangzhou’s founder, chairman, and CEO, along with Tan Zaiqiang, Innovent Biologics’ Vice President of Retail.

Two men shaking hands and holding red documents.

Fangzhou and Innovent Biologics formalized a strategic partnership

This alliance will combine Fangzhou’s AI-powered “H2H” digital healthcare ecosystem with Innovent’s portfolio of novel therapies for diabetes and obesity. It seeks to establish a groundbreaking model that integrates AI technology, innovative products, and tailored services. This partnership comes amid a rapidly growing weight management market in China, with JPMorgan projecting that the market for weight management drugs could achieve US$14.9 billion by 2030.

China has positioned weight management as a key public health initiative. In 2024, the National Health Commission, alongside 15 other departments, initiated a three-year “Weight Management Year” campaign. Subsequently, in April 2025, the National Patriotic Health Campaign Committee integrated healthy weight programs into its comprehensive “Healthy China” framework.

Dr. Xie Fangmin, Fangzhou’s founder, chairman, and CEO, remarked, “We are enthusiastic about this partnership with Innovent Biologics. Collaboratively, we aim to forge a new paradigm that merges innovative medicines with digital health to improve patient results.”

The initial phase of this collaboration will concentrate on diabetes and obesity. Fangzhou plans to implement its “XS Core” AI large language model, which supports five core products: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. These tools are designed to offer personalized, round-the-clock digital care and augment patient education.

Innovent’s advanced weight management therapy, Mazdutide, has shown substantial weight reduction and enhancements across several health indicators, including blood pressure, lipids, and uric acid[1]. The drug also received recognition as one of 2025’s “Top 10 Most Anticipated Medicines” worldwide.

Through this partnership, patients will receive convenient access to medication assistance via the AI Medication Finder, while the AI Health Manager will offer monitoring, tailored guidance, and educational resources to boost treatment adherence.

Moving forward, both companies intend to intensify their collaboration in AI-driven health management. This involves broadening access to innovative therapies and improving the quality and efficiency of chronic disease care throughout China.

About Innovent Biologics
Established in 2011, Innovent Biologics develops and commercializes pioneering therapies in oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology.

About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is recognized as China’s premier online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025. The Company specializes in providing customized medical care and precision medicine solutions. For additional details, please visit .

Media Contact
For further inquiries or interviews, please contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release includes forward-looking statements. Actual outcomes may vary significantly from those projected due to various influencing factors. Readers are advised against placing undue reliance on these statements.

[1] Linong Ji, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England Journal of Medicine. 2025